Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691156 · ClinicalTrials.gov registry record
Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 143
- Enrollment target
NCT02691156: Completed study, sponsored by Stanford University.
NCT02691156 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02691156 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 143 participants
- Enrollment target
Study Summary
Most preterm newborns are managed by phototherapy to reverse hyperbilirubinemia with the intent to prevent bilirubin neurotoxicity. A threshold-based relationship between a specific total bilirubin level and need for intervention has been elusive. This is most likely due to other biomarkers such as hemolysis, developmental maturation, concurrent illnesses, or even interventions, may impede bilirubin/albumin binding. The over-prescription of phototherapy has impacted clinical and family-centered care, and in the extreme preterm infants, it may have augmented their risk of mortality. Thus, the opportunity to individualize phototherapy in in order to reduce its use is unique. The investigators have assembled a transdisciplinary team to examine critical unanswered questions including the role of bilirubin binding capacity (BBC) of an individual during the first week of life in the context of clinical modifiers and antecedents for a domain of bilirubin-induced neurologic disorders, that includes neuro-anatomical, hearing, visual and developmental processing impairments. In this study, the investigator will evaluate two new innovative nanotechniques to quantify bilirubin load for the first time in the context of a clinical decision algorithm to identify those most at risk for any bilirubin-related neurotoxicity. The investigators anticipate that knowledge gained from this study will lead to ethically testable hypotheses to individualize the prescription of phototherapy.
Interventions
- DIAGNOSTIC_TEST Bilirubin Binding Capacity
- DIAGNOSTIC_TEST End-tidal Carbon Monoxide
- DIAGNOSTIC_TEST Carboxyhemoglobin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2018-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02691156
The ClinicalTrials.gov registry entry for NCT02691156 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bilirubin Binding Capacity is the first listed.
NCT02691156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02691156 about?
NCT02691156 is a clinical study titled "Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants". Most preterm newborns are managed by phototherapy to reverse hyperbilirubinemia with the intent to prevent bilirubin neurotoxicity. A threshold-based relationship between a specific total bilirubin level and need for intervention has been elusive. This is most likely due to other biomarkers such as ...
What is the current status of trial NCT02691156?
This trial is currently completed. The enrollment target is 143 participants. The study started on 2016-02-01. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02691156?
The interventions under investigation include: Bilirubin Binding Capacity (DIAGNOSTIC_TEST), End-tidal Carbon Monoxide (DIAGNOSTIC_TEST), Carboxyhemoglobin (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02691156?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.